Suppr超能文献

选择新辅助化疗后腋窝降期的前哨淋巴结阳性患者。

Selecting Node-Positive Patients for Axillary Downstaging with Neoadjuvant Chemotherapy.

机构信息

Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Biostatistics Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

出版信息

Ann Surg Oncol. 2020 Oct;27(11):4515-4522. doi: 10.1245/s10434-020-08650-z. Epub 2020 Jun 2.

Abstract

BACKGROUND

Axillary lymph node dissection (ALND) can be avoided in node-positive patients who receive neoadjuvant chemotherapy (NAC) if three or more negative sentinel lymph nodes (SLNs) are retrieved. We evaluate how often node-positive patients avoid ALND with NAC, and identify predictors of identification of three or more SLNs and of nodal pathological complete response (pCR).

METHODS

From November 2013 to July 2019, all patients with cT1-3, biopsy-proven N1 tumors who converted to cN0 after NAC received SLN biopsy (SLNB) with dual mapping and were identified from a prospectively maintained database.

RESULTS

630 consecutive N1 patients were eligible for axillary downstaging with NAC; 573 (91%) converted to cN0 and had SLNB, and 531 patients (93%) had three or more SLNs identified. Lymphovascular invasion (LVI; odds ratio [OR] 0.46, 95% confidence interval [CI] 0.24-0.87; p = 0.02) and increasing body mass index (BMI; OR 0.77, 95% CI 0.62-0.96 per 5-unit increase; p = 0.02) were significantly associated with failure to identify three or more SLNs. 255/573 (46%) patients achieved nodal pCR; 237 (41%) had adequate mapping. Factors associated with ALND avoidance included high grade (OR 2.51, 95% CI 1.6-3.94, p = 0.001) and receptor status (HR+/HER2- [referent]: OR 1.99, 95% CI 1.15-3.46 [p = 0.01] for HR-/HER2-, OR 3.93, 95% CI 2.40-6.44 [p < 0.001] for HR+/HER2+, and OR 8.24, 95% CI 4.16-16.3 [p < 0.001] for HR-/HER2+). LVI was associated with a lower likelihood of avoiding ALND (OR 0.28, 95% CI 0.18-0.43; p < 0.001).

CONCLUSIONS

ALND was avoided in 41% of cN1 patients after NAC. Increased BMI and LVI were associated with lower retrieval rates of three or more SLNs. ALND avoidance rates varied with receptor status, grade, and LVI. These factors help select patients most likely to avoid ALND.

摘要

背景

如果在前哨淋巴结活检(SLNB)中取出 3 个或更多阴性的前哨淋巴结(SLN),那么接受新辅助化疗(NAC)的淋巴结阳性患者可以避免腋窝淋巴结清扫(ALND)。我们评估了有多少淋巴结阳性患者通过 NAC 避免了 ALND,并确定了识别 3 个或更多 SLN 和淋巴结病理完全缓解(pCR)的预测因素。

方法

从 2013 年 11 月至 2019 年 7 月,所有经活检证实为 cT1-3、N1 期肿瘤且在 NAC 后转化为 cN0 的患者均接受了双标记 SLNB,并从一个前瞻性维护的数据库中进行了识别。

结果

630 例连续的 N1 患者有资格进行 NAC 降期治疗;573 例(91%)转化为 cN0 并进行了 SLNB,531 例(93%)有 3 个或更多 SLN 被识别。脉管侵犯(LVI;比值比 [OR] 0.46,95%置信区间 [CI] 0.24-0.87;p=0.02)和体重指数(BMI)的增加(OR 0.77,95% CI 每增加 5 个单位 0.62-0.96;p=0.02)与未能识别 3 个或更多 SLN 显著相关。255/573(46%)例患者达到了淋巴结 pCR;237 例(41%)有足够的标记。避免 ALND 的相关因素包括高分级(OR 2.51,95% CI 1.6-3.94,p=0.001)和受体状态(HR+/HER2-[参考]:OR 1.99,95% CI 1.15-3.46 [p=0.01] HR-/HER2-,OR 3.93,95% CI 2.40-6.44 [p<0.001] HR+/HER2+,和 OR 8.24,95% CI 4.16-16.3 [p<0.001] HR-/HER2+)。LVI 与较低的 ALND 避免率相关(OR 0.28,95% CI 0.18-0.43;p<0.001)。

结论

NAC 后,cN1 患者中有 41%避免了 ALND。BMI 的增加和 LVI 与 3 个或更多 SLN 的检出率较低有关。ALND 避免率随受体状态、分级和 LVI 而变化。这些因素有助于选择最有可能避免 ALND 的患者。

相似文献

1
Selecting Node-Positive Patients for Axillary Downstaging with Neoadjuvant Chemotherapy.
Ann Surg Oncol. 2020 Oct;27(11):4515-4522. doi: 10.1245/s10434-020-08650-z. Epub 2020 Jun 2.
6
Sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with node-positive breast cancer: guiding a more selective axillary approach.
Breast Cancer Res Treat. 2021 Apr;186(2):527-534. doi: 10.1007/s10549-020-06011-8. Epub 2020 Nov 9.
8
Decreasing Use of Axillary Dissection in Node-Positive Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
Ann Surg Oncol. 2018 Sep;25(9):2596-2602. doi: 10.1245/s10434-018-6637-9. Epub 2018 Jul 5.
10
Patterns of Axillary Management in Stages 2 and 3 Hormone Receptor-Positive Breast Cancer by Initial Treatment Approach.
Ann Surg Oncol. 2019 Dec;26(13):4326-4336. doi: 10.1245/s10434-019-07785-y. Epub 2019 Sep 27.

引用本文的文献

3
Real-World Assessment of Locoregional Management of the Axilla in Node-Positive Breast Cancer After Neoadjuvant Chemotherapy.
Ann Surg Oncol. 2025 Jun;32(6):3975-3983. doi: 10.1245/s10434-025-17041-1. Epub 2025 Feb 19.
10
Feasibility and accuracy of targeted axillary dissection in breast cancer patients; single center experience.
Front Surg. 2024 Jan 10;10:1332142. doi: 10.3389/fsurg.2023.1332142. eCollection 2023.

本文引用的文献

1
Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline Pathogenic Variant.
J Clin Oncol. 2020 Feb 10;38(5):388-394. doi: 10.1200/JCO.19.01304. Epub 2019 Aug 28.
5
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.
Ann Oncol. 2019 Aug 1;30(8):1194-1220. doi: 10.1093/annonc/mdz173.
7
Does Lymph Node Status Prior to Neoadjuvant Chemotherapy Influence the Number of Sentinel Nodes Removed?
Ann Surg Oncol. 2019 Feb;26(2):336-342. doi: 10.1245/s10434-018-7004-6. Epub 2018 Nov 30.
10
Decreasing Use of Axillary Dissection in Node-Positive Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
Ann Surg Oncol. 2018 Sep;25(9):2596-2602. doi: 10.1245/s10434-018-6637-9. Epub 2018 Jul 5.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验